|Bid||44.01 x 1800|
|Ask||44.04 x 900|
|Day's range||43.13 - 44.10|
|52-week range||41.98 - 58.10|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||16.11|
|Forward dividend & yield||1.75 (3.94%)|
|Ex-dividend date||26 May 2022|
|1y target est||67.88|
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Amid signs that a more severe influenza season is approaching in the US, a panel of public health leaders today urged that people get vaccinated in preparation for the upcoming influenza season and warned that patients in high-risk populations tend to suffer significant flu-related health disparities.3